Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 1 | 3 | 2 | 7 |
Psychotic disorders | D011618 | — | F20.81 | — | 1 | 1 | 2 | 1 | 5 |
Schizophrenia spectrum and other psychotic disorders | D019967 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 1 | 1 | — | — | 2 |
Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 2 | — | — | — | 2 |
Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 2 | — | — | — | 2 |
Sclerosis | D012598 | — | — | — | 2 | — | — | — | 2 |
Intellectual disability | D008607 | EFO_0003847 | F73 | — | 1 | — | — | — | 1 |
Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | 1 | — | — | — | 1 |
Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Long qt syndrome | D008133 | HP_0001657 | I45.81 | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
Tinnitus | D014012 | — | H93.1 | — | — | — | — | 1 | 1 |
Post-acute covid-19 syndrome | D000094024 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Pimozide |
INN | pimozide |
Description | Pimozide is a member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group. It has a role as a H1-receptor antagonist, a serotonergic antagonist, a first generation antipsychotic, an antidyskinesia agent and a dopaminergic antagonist. It is a member of benzimidazoles, an organofluorine compound and a heteroarylpiperidine. |
Classification | Small molecule |
Drug class | Typical antipsychotic |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 |
PDB | — |
CAS-ID | 2062-78-4 |
RxCUI | — |
ChEMBL ID | CHEMBL1423 |
ChEBI ID | 8212 |
PubChem CID | 16362 |
DrugBank | DB01100 |
UNII ID | 1HIZ4DL86F (ChemIDplus, GSRS) |